Acrivon Therapeutics, Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
ACRV$1.57-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(40,686) | $(35,284) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 646 | 452 |
| Stock-based compensation expense | 7,718 | 6,910 |
| Non-cash operating lease expense | 503 | 453 |
| Net amortization of premiums and accretion of discounts on investments | (533) | (1,676) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 1,169 | 413 |
| Accounts payable | 264 | (3,215) |
| Accrued expenses and other current liabilities | (4,844) | 1,384 |
| Operating lease liabilities | (382) | (423) |
| Net cash used in operating activities | (36,145) | (30,986) |
| Cash flows from investing activities: | ||
| Purchases of investments | (35,284) | (163,167) |
| Proceeds from maturities of investments | 74,500 | 81,925 |
| Purchases of property and equipment | (551) | (952) |
| Net cash provided by (used in) investing activities | 38,665 | (82,194) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock in private placement | — | 69,997 |
| Proceeds from issuance of pre-funded warrants in private placement | — | 60,003 |
| Proceeds from exercise of stock options | 1 | 90 |
| Payments of offering costs | — | (6,236) |
| Payments of tax withholdings related to vesting of restricted stock units | (441) | (676) |
| Net cash (used in) provided by financing activities | (440) | 123,178 |
| Net increase in cash, cash equivalents, and restricted cash | 2,080 | 9,998 |
| Cash, cash equivalents and restricted cash at beginning of period | 40,016 | 36,429 |
| Cash, cash equivalents and restricted cash at end of period | $42,096 | $46,427 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities | $722 | $123 |
| Deferred offering costs in accounts payable and accrued expenses and other current liabilities | $— | $308 |
| Reconciliation of cash, cash equivalents, and restricted cash: | ||
| Cash and cash equivalents | $41,895 | $46,006 |
| Restricted cash | 201 | 421 |
| Total cash, cash equivalents, and restricted cash | $42,096 | $46,427 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.